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Abstract
Background and objective  cyclin D1 is a member of the cyclin family, and it has been proven that it plaied an important role in 
tumorigenesis, invasion and metastasis. We performed a retrospective study on the cyclin D1 expression in non-small cell lung 
cancer (NSCLC) according to the clinical characteristics.
Methods  One hundred fifteen postsurgical NSCLC patients were investigated. Immunohistochemistry was used to evaluate the 
cyclin D1 expression. 
Results  Overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1 
low expression of tumors (χ
2=5.132, P=0.023). In early stage patients (stage I, II), the overall survival was significantly lower in 
patients with cyclin D1-high expression of tumors than those with cyclin D1-low expression of tumors (χ
2=6.863, P=0.009). 
cyclin D1 status (hazard ratio=0.630; P=0.035), differentiation (hazard ratio=0.399; P<0.001), and pTNM (hazard ratio=1.576; 
P<0.001) to be independent prognostic factors for NSCLC patients. Specifically, the cyclin D1 status (hazard ratio=0.188; 
P=0.008) was a significant prognostic factor for patients with stage I NSCLCs.  
Conclusion  cyclin D1 expression is an independent prognosis factor for postoperative patient in stage I, II NSCLCs.
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Background
Lung cancer is a leading cause of death due to cancer 
(1.4 million deaths/each year) [1]. Thereinto, non-small cell 
lung cancer (NSCLC) accounts for 85%. But at present, 
chemotherapy, radiotherapy, and surgery are the first priorities 
in the medical treatment. The choice of the treatment is 
determined by TNM (tumor-node-metastasis) stage[2]. 
Unfortunately, the effect of treatment for NSCLC is far from 
perfect. The 5-year survival rates for stage I, II, III are 47%, 26% 
and 8.4% respectively[3]. Therefore, much importance should 
be attacked to the further clarification of the mechanism of 
tumor biology and its pathogenesis, and the study on the 
factors which will affect the prognosis, in expectation of giving 
more pertinent and timely treatment, improving the prognosis 
and prolonging the survival period of NSCLC patients. The 
cyclin is an important protein to regulate the cell cycle. At 
different stages of cell mitosis, the components of cyclin family 
intergrate with cyclin-dependent kinases (CDK), and form a 
complex acting as a regulatory subunit of CDK. cyclin D1 is an 
indispensable regulatory protein to cell cycle in G1/S transition. 
It forms a complex with CDK4 or CDK6, which phosphorylates 
retinoblastoma protein which is involved in STAT5A-regulated 
transcription. Overexpression of cyclin D1 could alter the 
process of the cycle and induce excessive proliferation of cell or 
even tumor[4]. The current research shows that down-regulating 
the expression of cyclin D1 could restrain proliferation of tumor 
cells[5]. Another study found cancers with higher indexes of 
cyclin D1 expression have the stronger capacity to metastasize[6]. 
Therefore, there comes the hypothesis that the expression of 
cyclin D1 in lung cancer cell could impact the survival time 
of lung cancer patients. The aim of this study is to evaluate 
the expression of cyclin D1 in lung cancer tissues by means of 
immunohistochemistry, and to analyze the relationship between 
the amount of tumor staining for cyclin D1 and overall survival.
Materials and Methods 
Patients  
A total of 115 tumor specimens were obtained from the 
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patients who had undergone surgeries at Nanjing Chest 
Hospital and No. 81 Hospital of PLA from January 2001 
to December 2005. None of the in-patients with NSCLC 
received any chemotherapy or radiotherapy before their 
surgeries, and all of them had surgeries as their first 
line of management. The patients’ characteristics are 
presented in Table 1. The patients included 87 males 
and 28 females, aged 17-80 years (mean 59.7 years). 
According to the classification of the World Health 
Organization (WHO), the specimens were classified 
into 63 (54.8%) adenocarcinomas (of that, 13 tumors 
were BAC), 40 (34.8%) squamous cell carcinomas, 12 
(10.4%) others (large cell carcinomas, adenosquamous 
carcinomas and carcinoid). The p-Stage and pN-Stage were 
determined according to the guidelines of the American 
Joint Committee on Cancer[7]. 105 (91.3%) patients 
received postoperative adjuvant chemotherapy by the 
third generation of platinum-based regimens. Inclusion 
criteria for this study were surgical complete resection of 
the tumor (resection margin microscopically free of tumor 
cells); survived for more than 3 months after surgery; not 
dying of causes other than lung cancer within 5 years after 
surgery. The patients’ clinical records and histopathological 
diagnoses were fully documented. The date of last follow-
up was March 21, 2008.
Immunohistochemical staining  
Antibodies for immunohistochemical analyses were 
obtained. As follows: rabbit anti-human cyclin D1 monoclonal 
antibody (working solution, ZA-0101, Zhongshan 
Goldenbridge Biotechnology, Beijing, China), rabbit anti-
human caveolin-1 polyclonal antibody (1:300, N-20: sc-894, 
Santa Cruz Biotechnology, Santa Cruz, USA). Resected 
specimens were fixed in 10% formalin, and paraffin-embedded 
blocks were prepared. Next, 4 μm thick sections were cut 
from the specimens and placed on slides coated with poly-
L-lysine. Immunohistochemical staining was performed by 
using the EnVision two-step procedure immunohistochemical 
method (EnVision Detection Kit, Peroxidase/DAB, Rabbit/
Mouse, DAKO, Denmark), and the operations were carried 
out strictly following the manufacturer’s instructions. In 
brief, sections were routinely deparaffinized with xylene and 
rehydrated in decreasing concentrations of alcohol. Antigen 
retrieval was done by placing the specimen in EDTA retrieval 
agent (ZLI-9066_ZLI-9067, Zhongshan Goldenbridge 
Biotechnology, Beijing, China) at pH8.0, and autoclaved at 
12 oC for 2 min to allow for fixing. The sections were washed 
in phosphate-buffered saline (PBS) buffer (pH7.6), then 
the sections were incubated overnight at 4 oC in a moist 
chamber with the antibody. After washing the sections in 
PBS three times for 5 min, they were treated for 30 min at 
room temperature in ChemMate EnVision+/HRP (DAKO, 
Denmark). Subsequently, the sections were washed with PBS, 
and DAB colorization was applied, followed by application 
of diaminobezidine (DAB) solution (ChemMate EnVision+/
DAB, DAKO, Denmark) until color developed. Staining was 
monitored under a bright-field microscope, and the reaction 
was stopped by washing with distilled water. The sections 
were then counterstained with hematoxylin; dehydrated in 
increasing concentrations of alcohol, and coversliped with 
neutral gummy.
Immunohistochemial staining evaluation  
The slides were independently reviewed by two of the 
authors (P.Z. and Q.W.) who had no knowledge of the patients’ 
clinicopathological status. If the discrepancies existed between 
the reviewers, a consensus judgment was reached through 
discussion. The proportion of staining tumor cells in each 
selected field was determined by counting individual tumor 
cells at randomly chosen 4 high magnification (×400) fields 
by using a light microscope (Model CX31RTSF, Olympus, 
Tokyo, Japan). The immunoreactivities were graded as (-), (+), 
(++), (+++) according to the percentage of the positive tumor 
cells: (-) represents zero or less than 5% positive tumor cells; 
(+) represents 5%-25% positive tumor cells; (++) represents 
25%-50% positive tumor cells; and (+++) represents the 
strongest staining with more than 50% positive tumor cells. 
    For cyclin D1[6], the samples of breast cancer (whose cells 
had positive nuclear staining for cyclin D1) were referred to as 
a positive control, while the negative controls were included by 
omission of the primary antibody. More than 5% of tumor cells 
(+) showed definitive nuclear positivity, which was considered 
cyclin D1 high expression.
Statistical analysis  
Statistical analysis was performed using the SPSS for 
Windows v.13.0 package program. Chi-square test was used for 
comparison of data between groups. Overall survival (OS) was 
calculated from the day of surgery to the date of last follow-
up or the date of death. While death of no recurrence patients 
or survival at last follow-up date is considered to be censored. 
OS curves were computed according to the method of Kaplan-
Meier. To assess the independent value of different variables on 
survival in the presence of other variables, multivariate analysis 
was carried out using the Cox proportional hazards model. 
Analysis was performed using backward Wald’s criteria. A value 
of P<0.05 was accepted as statistically significant, and all tests 
were two-sided.
Results
 
Follow-up  
Median time of follow-up was 22 months (rangeing from 3 
to 83 months). 30 cases were censored, accounting for 26.1% 
of all the patients.
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cyclin D1 expression in NSCLCs  
cyclin D1 staining featured a heterogeneous nuclear staining 
pattern (Fig 1) in tumor cells. 55 cases were high expression, 
accounting for 47.8% of all the 115 cases with NSCLCs. 60 
cases were low expression, with a percentage of 52.2%. There is 
no significant difference in the cyclin D1 expression in relation 
to gender (P=0.830), smoke habit (P=0.190), tumor status 
(P=0.373), nodal status (P=0.444), histology (P=0.058), 
pathologic stage (P=0.130) or differentiation (P=0.850).
Overall survival of NSCLC patients in relation to cyclin D1 
status  
The overall survival was significantly lower in patients with 
cyclin D1-high expression of tumors than in those with cyclin 
D1-low expression of tumors (P=0.023) (Fig 2a, Tab 2). In 
early stages (stage I, II), the overall survival of the patients 
with cyclin D1-high expression of tumors was significantly 
lower than those with cyclin D1-low expression of tumors 
(P=0.009) (Fig 2b, Tab 2). Multivariate regression analysis 
based on the Cox proportional hazards regression model 
demonstrated that the cyclin D1 status (hazard ratio=0.630; 
P=0.035), differentiation (hazard ratio=0.399; P<0.001), 
and pTNM (hazard ratio=1.576; P<0.001) were independent 
prognostic factors for NSCLC patients (Tab 3). Especially 
the cyclin D1 status (hazard ratio=0.188; P=0.008) was a 
significant prognostic factor for patients with stage I NCSLC 
(Tab 4).
Discussion
Many researches showed that intratumoral cyclin D1 levels 
were correlated with the outcome of prognosis. Brücher BL 
et al found, low cyclin D1 levels experienced significantly less 
frequent recurrence of the tumor, and there was a significant 
difference in the recurrence-free interval[9]. Jaworska et al 
evaluated cyclin D1 levels of 47 specimens of resected oral 
and lip squamous cell carcinoma by immunohistochemistry 
and their pertinence with survival time of patients. The 
findings indicated that lower expression of cyclin D1 was 
correlated with longer disease free survival[10]. Rudas et al used 
immunohistochemistry to assess the expressions of cyclin D1 
in surgical specimens from patients with breast carcinomas 
and colorectal cancers that received adjuvant chemotherapy 
by Tamoxifen, and patient survival. They found that the 
overall survival and Relapse-free survival of patients with 
positive cyclin D1 were shorter, compared with the patients 
with negative cyclin D1[11]. García et al used real-time PCR to 
examine the cyclinD1 mRNA in plasma of patients with breast 
cancers. They observed poor outcomes in patients with the 
Fig 1  Immunostaining of NSCLC in serial sections. A: negative contrast; B: adenocarcinoma with positive expression of cyclin D1; C: squamous cell 
carcinoma with positive expression of cyclin D1.
A B C
Fig 2  Overall survival of 115 NSCLC patients in relation to cyclin D1 status. A: in total of 115 NSCLC patients; B: in 63 patients with stage I, II NSCLCs; 
C: in 52 patients with stage III, IV NSCLCs.
A B C
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Tab 2  Survival analysis of 115 patients with non-small cell lung cancer
Parameter n Deaths Survival time (month) Log-rank test
Mean (95% CI) Median (95% CI) χ 2 P
All pateints 115 85 35.27 (29.91-40.63) 23.00 (17.01-28.91) 5.132 0.023
    cyclin D1 low expression   60 39 39.86 (32.50-47.23) 29.00 (12.07-45.93)
    cyclin D1 high expression   55 46 29.02 (22.19-35.869) 20.00 (15.97-24.05)
Stage I， II   63 39 44.75 (36.96-52.54) 40.00 (23.27-56.73) 6.863 0.009
    cyclin D1 low expression   31 15 53.45 (43.90-63.00) 72.00 (45.84-98.16)
    cyclin D1 high expression   32 24 34.39 (23.94-44.84) 23.00 (17.70-28.30)
Stage III， IV   52 46 22.27 (17.67-26.88) 17.00 (13.47-20.53) 0.091 0.763
    cyclin D1 low expression   29 24 22.95 (16.08-29.82) 16.00 (9.41-22.59)
    cyclin D1 high expression   23 22 21.52 (15.31-27.73) 19.00 (15.48-22.52)
Variables No. of patients (%) cyclin D1 P 
Low                   high
   All patients 115 (100)     60 55
Gender 0.791
    Male 87 (75.7) 46  41
    Fmale 28 (24.3) 14  14
Age 0.987
    <60  44 (38.3) 23 21
    ≥60  71 (61.7) 37 34
Smoking 0.181
    Non-smoker 47 (40.9) 21 26
    Smoker 68 (59.1) 39 29
Size of tumor 0.169
    ≤3 cm 32 (27.8) 20 12
    >3 cm 83 (72.2) 40 43
T-stage 0.277
    T1, T2 89 (77.4) 44 45
    T3, T4 26 (22.6) 16 10
Histology 0.058
    Squamous cell carcinoma 40 (34.8) 24 16
    Adenocarcinoma 63 (54.8) 27 36
    Other 12 (10.4)   9   3
N-stage 0.418
    N0 42 (36.5) 24 18
    N1+N2 73 (63.5) 36 37
p-TNM stage 0.130
    I 36 (31.3) 20 16
    Ia 13 10   3 0.083*
    Ib 23 10 13
    II 27 (23.5) 11 16
    III 41 (35.7) 20 21
    IV 11 (9.6)    9   2
Bronchoalveolar carcinoma 0.293
    Yes 13 (11.3)   5   8
    No 102 (88.7) 55 47
Differentiation 0.717
    Well/Moderate 67 (58.3) 26 22
    Poor 48 (41.7) 34 33
*Fisher's Exact Test.
Tab 1  Distribution of 115 non-small cell lung cancer patients according to cyclin D1 status
CI: confidence interval.
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Tab 3  Multivariate regression analysis in predicting survival of 115 patients with 
NSCLC
B P  Hazard ratio 95% CI
cyclin D1 status -0.461     0.035※ 0.630 0.411-0.967
Differentiation -0.920 <0.001 0.399  0.248-0.641
pTNM   0.455 <0.001 1.576 1.255-1.980
B: partial regression coefficient; ※: low expression versus high expression.
presence of cyclinD1 mRNA in plasma among good-prognosis 
group (such as negative vascular invasion). Furthermore, the 
presence of cyclin D1 mRNA was correlated with relapse after 
surgery and insensitivity to Tamoxifen[12]. In the researches 
mentioned above, without exception, observed specimens 
are completely resected tumor. The main factor influencing 
survival time was recurrence. Also, regarding the lung cancer 
cases of completely resected stage I, the rate of recurrence after 
surgery is 25%-50%. It’s probably because of occult extensiver 
disease undetected by traditional method at the time of 
surgery, including local and distant metastasis[13]. A meta-
analysis indicated that 20%-70% stage I NSCLC patients were 
found micrometastasis in lymph nodal. The 3-, 5-years overall 
survival rate for positive patients was worse than negative 
patients[14]. cyclin D1 may play a leading role in mediating 
invasion and metastasis of cancer cells[15].  Parra et al found 
cyclin D1 expression of non-metastatic adenocarcinomas 
was lower than metastatic adenocarcinomas. Kaplan-Maier 
analysis revealed patients with higher cyclin D1 expression 
were significantly shorter (P=0.04) [6].  Another study 
indicated that cyclin D1 promotes cellular motility through 
inhibiting ROCK signaling and repressing the metastasis 
suppressor TSP-1[16]. Luo et al recently reported that Twist 
protein promoted the migration, invasion, and metastasis of 
the gastric cancer cells. Furthermore, overexpression of Twist 
promoted the expression of cyclin D1, while suppression of 
Twist inhibited the expression of cyclin D1[17]. It is obvious 
that high expression of intratumoral cyclin D1 not only 
directly promotes metastasis, but it is also an exhibition of 
activity of other factors related to promoting metastasis. It was 
presumed that cancer cells with higher expression of cyclin D1 
have stronger capacity for metastasis and earlier occurrence 
of micro metastasis than those with lower expression of cyclin 
D1. Despite the complete resection of the primary tumor, the 
focus of micrometastasis is still present as a potential cause 
of recurrence, and finally influences the prognosis. Our study 
revealed that high expression of cycinD1 was associated with 
a poor prognosis in early stage NSCLC patients. The level 
of cyclin D1 could be a useful index to distinguish patients, 
whose clinical outcome is poor, at stage I of NSCLCs’ 
complete resection. Whether high expression of cyclin D1 
is an index which can guide the postoperative adjuvant 
chemotherapy needs much more researches.
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